The present invention lies within the field of colloidal assemblies and relates to a system for producing solid clusters of microparticles, characterized in that it comprises at least: a fluidic device comprising at least: an element for producing primary droplets, comprising an outlet of width l.sub.1 and a main channel for forming solid clusters, having a main axis, of height h.sub.2 and comprising an inlet of width l.sub.2; said element for producing primary droplets being connected to said inlet of said main channel, h.sub.1 being less than h.sub.2, so as to form a step between said element for producing primary droplets and said main channel and l.sub.1 being strictly less than l.sub.2; a system of physical initiation of polymerization capable of initiating polymerization in said main channel.

The present invention lies within the field of colloidal assemblies and relates to a system for producing solid clusters of microparticles, characterized in that it comprises at least: a fluidic device comprising at least: an element for producing primary droplets, comprising an outlet of width l.sub.1 and a main channel for forming solid clusters, having a main axis, of height h.sub.2 and comprising an inlet of width l.sub.2; said element for producing primary droplets being connected to said inlet of said main channel, h.sub.1 being less than h.sub.2, so as to form a step between said element for producing primary droplets and said main channel and l.sub.1 being strictly less than l.sub.2; a system of physical initiation of polymerization capable of initiating polymerization in said main channel.

A hinge dampening device is provided for a granulation processor having a bowl and a lid. A dampening device includes first and second spaced apart hinge supports fixed to the bowl and a pin extending through the lid collar residing between the hinge supports. The first end of the pin is fixed to the first hinge support, and a second end of the pin extends through the second hinge support. An adjustable compressive force is applied axially to the hinge supports and lid collar to create frictional resistance to rotation of the lid. The rotational resistance provides controlled opening and closing of the lid.

A hinge dampening device is provided for a granulation processor having a bowl and a lid. A dampening device includes first and second spaced apart hinge supports fixed to the bowl and a pin extending through the lid collar residing between the hinge supports. The first end of the pin is fixed to the first hinge support, and a second end of the pin extends through the second hinge support. An adjustable compressive force is applied axially to the hinge supports and lid collar to create frictional resistance to rotation of the lid. The rotational resistance provides controlled opening and closing of the lid.

A method for emptying a device for producing granules or extrudates. The device includes a container having an inlet for the material to be treated, an inlet for a liquid, a stirring device, an outlet for said intermediate product, and an emptying pipe having an inlet for the intermediate product and an outlet for the granules or extrudate as well as a conveying device conveying the intermediate product from the inlet of the emptying pipe in the direction of the outlet of the emptying pipe. The method includes the steps of: producing the intermediate product from the material to be treated and the liquid in the container; moving the emptying pipe from the closed position with respect to the container into an open position with respect to the container; and conveying the intermediate product from the container and via the conveying devices.

A method for emptying a device for producing granules or extrudates. The device includes a container having an inlet for the material to be treated, an inlet for a liquid, a stirring device, an outlet for said intermediate product, and an emptying pipe having an inlet for the intermediate product and an outlet for the granules or extrudate as well as a conveying device conveying the intermediate product from the inlet of the emptying pipe in the direction of the outlet of the emptying pipe. The method includes the steps of: producing the intermediate product from the material to be treated and the liquid in the container; moving the emptying pipe from the closed position with respect to the container into an open position with respect to the container; and conveying the intermediate product from the container and via the conveying devices.

The disclosure provides continuous mixers and methods of using thereof including in the production of coated particles and proppants used in hydraulic fracturing techniques, by the application of coatings along the length of the continuous mixer through the use of a plurality of paddles configured within the continuous mixer.

The disclosure provides continuous mixers and methods of using thereof including in the production of coated particles and proppants used in hydraulic fracturing techniques, by the application of coatings along the length of the continuous mixer through the use of a plurality of paddles configured within the continuous mixer.

Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. In another embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, carboxymethylcellulose sodium, hydroxypropylmethylcellulose, citric acid monohydrate, disodium hydrogen phosphate, sucralose, sodium methyl parahydroxybenzoate, sodium ethyl parahydroxybenzoate, concentrated hydrochloric acid, sodium hydroxide, and water.

Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. In another embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, carboxymethylcellulose sodium, hydroxypropylmethylcellulose, citric acid monohydrate, disodium hydrogen phosphate, sucralose, sodium methyl parahydroxybenzoate, sodium ethyl parahydroxybenzoate, concentrated hydrochloric acid, sodium hydroxide, and water.